Rybelsus dosing changes: what the TikTok gets right and wrong

What did @olt_pharma actually say?

The creator claims a new Rybelsus formulation launched in September 2025 has significantly reduced tablet strengths across the board. Specifically: 3mg becomes 1.5mg, 7mg becomes 4mg, and 14mg becomes 9mg. They also say the tablets look different, the boxes are smaller, and GPs will automatically update prescriptions. Old stock stays available until end of January 2026.

This is a fairly specific, clinical claim. The creator presents themselves as a pharmacy professional, and the framing is authoritative, not speculative. Viewers taking Rybelsus for type 2 diabetes would reasonably act on this information, so accuracy matters a great deal here.

Does the science back this up?

This is where things get genuinely complicated. As of the knowledge cutoff relevant to this analysis, there is no publicly confirmed FDA or MHRA regulatory filing documenting a reformulation of oral semaglutide (Rybelsus) with these exact new dose strengths. That does not automatically mean it is false, but it means the claim is difficult to independently verify from published sources.

What we do know from the literature: Rybelsus (oral semaglutide) relies on the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) to survive the gastric environment. Davies et al. (2019, NEJM) established the dose-response relationship for the original 3mg, 7mg, and 14mg doses in the PIONEER trials. Any reformulation affecting bioavailability would require new pharmacokinetic data to justify dose equivalence. The creator does not mention bioavailability or clinical equivalence at all, which is a significant omission if a reformulation genuinely changed the tablet composition.

What did they get wrong (or right)?

The creator deserves credit for flagging that patients should be aware of prescription changes and for noting that old stock has a wind-down period. Those are responsible things to say. However, there are real problems here.

First, the dose mapping is stated as fact without any sourcing. We are told the 7mg "will now become 4mg" with zero explanation of whether these new doses are therapeutically equivalent. That matters enormously for glycemic control in diabetic patients. Second, saying GPs will change prescriptions "automatically in practice" could cause patients to stop verifying their own medication changes, which is risky advice regardless of whether the underlying claim is true.

Third, and most concerning: if this is a genuine reformulation with new bioavailability data, the creator does not mention it. If it is not, these dose numbers could reflect a regional supply change, a different market formulation, or simply be inaccurate. Presenting it as settled fact without a cited source from Novo Nordisk, the MHRA, or the FDA is a real journalistic problem.

What should you actually know?

If you are currently taking Rybelsus for type 2 diabetes, do not adjust your dose based on a TikTok video, regardless of the creator's credentials. Oral semaglutide dosing is tied to specific absorption protocols, including the requirement to take it on an empty stomach with plain water and wait 30 minutes before eating. Any change to dose or formulation should come directly from your prescriber or pharmacist with a written prescription update.

Novo Nordisk has been developing next-generation oral GLP-1 formulations, and it is plausible that updated products are entering certain markets. But "plausible" and "verified" are not the same thing. If your GP or pharmacist has not mentioned a change, ask them directly before assuming your prescription is outdated. The MHRA product information pages and the FDA's drug database are free and publicly accessible for checking approved formulations.

• Always confirm prescription changes with your dispensing pharmacist before assuming an update is correct.
• Novo Nordisk product communications and MHRA/FDA approval databases are the authoritative sources for formulation changes.
• The original PIONEER trial data (Davies et al., 2019, NEJM) was built on 3mg, 7mg, and 14mg doses. New dose strengths would require new efficacy and safety data to be considered equivalent.